Pathology & Lab Medicine Knowledge & Practice

• 10.50 90.50
  Key Updates for Community Practice: Identifying and Treating Patients With NTRK Gene Fusions
  Medscape Education Oncology June 29, 2023
  Do you know when to test your patients for neurotrophic tyrosine receptor kinase (NTRK) gene fusions?
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 10.50 90.50 30.50
  Biomarkers in NSCLC: From Detection to Novel Therapeutics and Decision-Making
  Medscape Education Oncology June 29, 2023
  Get the latest information from Chicago on targeted therapies for non-small cell lung cancer (NSCLC)!
  
  0.50 CME/CEMIN 0.50 ABIM MOCMIN 0.50 CEMIN

  
  Save
• 11.25 91.25
  Mission -- Impossible to Possible: Using Immunotherapy for the Treatment of Nonmelanoma Skin Cancers
  Medscape Education Oncology June 21, 2023
  Did you know that the vast majority of basal cell carcinoma (BCC) lesions are highly curable and easy to treat?
  
  1.25 CMEMIN 1.25 ABIM MOCMIN

  
  Save
• 10.25 90.25
  Moving Earlier in the Disease Landscape: Understanding Adjuvant Immunotherapy for Non-Small Cell Lung Cancer
  Medscape Education May 30, 2023
  Do you know what adjuvant treatment options are available for early-stage non-small cell lung cancer (NSCLC)? Join this program on developments in adjuvant treatment to learn more.
  
  0.25 CMEMIN 0.25 ABIM MOCMIN

  
  Save
• 10.50 90.50
  Multiple Myeloma: An Expert Discussion on the Role of Cytogenetics and Minimal Residual Disease
  Medscape Education Oncology May 25, 2023
  Learn the what, when, and how of multimodal disease assessment in the hematopathology lab for your patients with myeloma.
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 10.50 90.50
  Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver Mutations
  Medscape Education Oncology May 01, 2023
  Do you understand the role of non-targetable driver mutations in the management of acute myeloid leukemia (AML)?
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 10.75 90.75
  Designing and Using Antibody-Drug Conjugates to Treat Solid Tumors
  Medscape Education Oncology April 28, 2023
  How much do you know about antibody-drug conjugates (ADCs) for solid tumor management?
  
  0.75 CMEMIN 0.75 ABIM MOCMIN

  
  Save
• 10.25 90.25
  Hone Your Skills: Individualizing Care for Patients With KRAS G12C-Mutated NSCLC in the Community
  Medscape Education Oncology April 28, 2023
  KRAS G12C-mutated NSCLC: do you know best practices for patient care?
  
  0.25 CMEMIN 0.25 ABIM MOCMIN

  
  Save
• 10.50 90.50
  Metastatic Melanoma: Incorporating Lymphocyte-Activation Gene 3 Inhibitors Into the Treatment Paradigm
  Medscape Education Oncology April 21, 2023
  Are you up to date on the use of lymphocyte-activation gene 3 (LAG3) inhibitors to treat patients with metastatic melanoma?
  
  0.50 CMEMIN 0.50 ABIM MOCMIN

  
  Save
• 10.25 90.25
  Let's Talk Relapsed/Refractory Chronic Lymphocytic Leukemia: Expert Perspectives on Reversible BTK Inhibitors
  Medscape Education Oncology April 12, 2023
  Did you know studies have shown that noncovalent BTK inhibitors are efficacious in patients with covalent BTK inhibitor-pretreated CLL?
  
  0.25 CMEMIN 0.25 ABIM MOCMIN

  
  Save
• 10.75 90.75 20.75 30.75
  Immunotherapy in Non-Small Cell Lung Cancer
  Medscape Education Oncology March 31, 2023
  Increase your clinical acumen with these engaging presentations on NSCLC.
  
  0.75 CME/CEMIN 0.75 ABIM MOCMIN 0.75 CEMIN 0.75 CEMIN

  
  Save
• 10.50 90.50 20.50 30.50
  Hot Topics in Lung Cancer
  Medscape Education Oncology March 31, 2023
  Hear the most recent and impactful developments for lung cancer care in this captivating series.
  
  0.50 CME/CEMIN 0.50 ABIM MOCMIN 0.50 CEMIN 0.50 CEMIN

  
  Save
• 10.75 90.75 20.75 30.75
  Targeted Therapies 201: What's New and on the Horizon
  Medscape Education Oncology March 31, 2023
  Find out about new and exciting innovations in targeted therapies from these informative presentations.
  
  0.75 CME/CEMIN 0.75 ABIM MOCMIN 0.75 CEMIN 0.75 CEMIN

  
  Save
• 10.50 90.50 20.50 30.50
  Management of Small Cell Lung Cancer
  Medscape Education Oncology March 31, 2023
  Hear about pioneering efforts to address the challenges of small cell lung cancer care in these immersive presentations.
  
  0.50 CME/CEMIN 0.50 ABIM MOCMIN 0.50 CEMIN 0.50 CEMIN

  
  Save
• 11.00 91.00 21.00 31.00
  Targeted Therapies 101 
  Medscape Education Oncology March 31, 2023
  Do you know the latest information on targeted therapies for mNSCLC?
  
  1.00 CME/CEMIN 1.00 ABIM MOCMIN 1.00 CEMIN 1.00 CEMIN

  
  Save
• 11.25 91.25 21.25 31.25
  Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management
  Medscape Education Oncology March 30, 2023
  Eager to learn more about managing small cell lung cancer (SCLC)? Get ready with these cutting-edge talks.
  
  1.25 CME/CEMIN 1.25 ABIM MOCMIN 1.25 CEMIN 1.25 CEMIN

  
  Save
• 10.50
  Relapsed/Refractory Mantle Cell Lymphoma: Where Do Novel BTK Inhibitors Fit for Our Patients?
  Medscape Education Oncology March 30, 2023
  Have you heard about the newest noncovalent Bruton tyrosine kinase (BTK) inhibitor that has been added to the selection of BTK inhibitors used to treat relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
  
  0.50 CMEMIN

  
  Save
• 10.75 90.75 20.75
  Conceptualizing Guidelines to Manage Patients With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
  Medscape Education Oncology March 29, 2023
  What do the guidelines say about treating patients with early breast cancer at high risk for recurrence?
  
  0.75 CME/CEMIN 0.75 ABIM MOCMIN 0.75 CEMIN

  
  Save
• 10.25 90.25
  Quickfire: NTRK Updates Relevant for Your Practice
  Medscape Education Oncology March 27, 2023
  Do you know how to manage patients with solid tumors and NTRK fusions?
  
  0.25 CMEMIN 0.25 ABIM MOCMIN

  
  Save
• 10.25 90.25
  A Primer on Oral Selective Estrogen Receptor Degraders in Metastatic Hormone Receptor-Positive Breast Cancer
  Medscape Education Oncology March 23, 2023
  Aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). How do they work and when should they be added to the treatment of metastatic hormone receptor (HR)-positive breast cancer?
  
  0.25 CMEMIN 0.25 ABIM MOCMIN

  
  Save